9 stories found
Swiss pharmaceutical giant Roche, through its subsidiary Genentech, has secured global rights to develop and market an experimental obesity treatment from South Korean company Hanmi Pharmaceuticals.
Roche's Genentech unit announced plans to construct a new $750 million fill-finish facility in Ohio, expanding its manufacturing capabilities.
Genentech has received approval for a new bladder cancer indication for its drug, Tecentriq, expanding its therapeutic use.
Hanmi Pharmaceutical's shares experienced a significant jump following the announcement of a $2.31 billion licensing agreement with Genentech, a major biotechnology company.
Recursion has outlined its 2026 cash operating expenses guidance at $375 million. The company is also advancing its first neuroscience target in collaboration with Genentech.
The TrumpRx initiative has reportedly added medicines from pharmaceutical giants AbbVie and Roche’s Genentech to its offerings.
Hanmi Pharm has signed a record-breaking $2.3 billion (3.2 trillion won) exclusive licensing deal with Roche's Genentech for its novel obesity drug candidate. Following the announcement, Hanmi Pharm's shares jumped by 30%.
Immunic has announced the appointment of Erik Lundgren, a former Genentech executive, as its new Chief Executive Officer, tasked with advancing the company's Phase 3 MS trials.
Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy, alleging illegal importation of a Canadian version of their allergy medicine.